ALDX:NSD-Aldeyra Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.51

Change

+0.05 (+1.45)%

Market Cap

USD 0.19B

Volume

1.05M

Avg Analyst Target

USD 20.00 (+469.80%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aldeyra Therapeutics Inc (ALDX) Stock Analysis:
Based on the Aldeyra Therapeutics Inc stock forecasts from 2 analysts, the average analyst target price for Aldeyra Therapeutics Inc is USD 20.00 over the next 12 months. Aldeyra Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aldeyra Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Aldeyra Therapeutics Inc’s stock price was USD 3.51. Aldeyra Therapeutics Inc’s stock price has changed by +0.02% over the past week, -0.66% over the past month and -70.03% over the last year.

About

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry e ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.76 (-3.03%)

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

-18.29 (-2.94%)

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.57 (-1.12%)

USD57.63B 27.19 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+5.51 (+3.65%)

USD36.62B 4.77 5.67
BGNE BeiGene Ltd

-15.38 (-6.18%)

USD25.75B N/A N/A
SGEN Seagen Inc

-4.45 (-3.43%)

USD23.69B 55.02 44.86
GMAB Genmab A/S

-1.55 (-4.54%)

USD22.21B 50.69 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.34 (-0.86%)

USD16.38B 19.81 11.89

ETFs Containing ALDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.25% 70% C- 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.25% 70% C- 41% F
Trailing 12 Months  
Capital Gain -70.03% 30% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.03% 30% F 14% F
Trailing 5 Years  
Capital Gain -38.42% 47% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.42% 47% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 38.33% 72% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.33% 72% C- 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 96.37% 28% F 16% F
Risk Adjusted Return 39.78% 71% C- 59% F
Market Capitalization 0.19B 48% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.83 71% C- 59% F
Price / Cash Flow Ratio -5.04 51% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -36.92% 70% C- 27% F
Return on Invested Capital -49.83% 48% F 17% F
Return on Assets -18.76% 67% D+ 20% F
Debt to Equity Ratio 19.21% 41% F 59% F
Technical Ratios  
Short Ratio 1.34 74% C 68% D+
Short Percent 5.26% 41% F 31% F
Beta 1.52 35% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector